{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:25:51Z","timestamp":1719361551153},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,25]]},"DOI":"10.7759\/cureus.63120","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:01:17Z","timestamp":1719327677000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment Challenges in Alopecia Areata: Insights From a Case of Baricitinib Therapy Failure"],"prefix":"10.7759","author":[{"given":"Deesha D","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambika","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen I","family":"Lo Sicco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Olumiant (baricitinib) FAQ - National Alopecia Areata Foundation. (2024). Accessed. June 24, 2024: https:\/\/www.naaf.org\/olumiant-baricitinib-faq\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417716363","article-title":"A case of topical ruxolitinib treatment failure in alopecia areata","volume":"21","author":"Deeb M","year":"2017","unstructured":"Deeb M, Beach RA. A case of topical ruxolitinib treatment failure in alopecia areata. J Cutan Med Surg. 2017, 21:562-3. 10.1177\/1203475417716363","journal-title":"J Cutan Med Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.047","article-title":"Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review","volume":"85","author":"Toussi A","year":"2021","unstructured":"Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review. J Am Acad Dermatol. 2021, 85:162-75. 10.1016\/j.jaad.2020.06.047","journal-title":"J Am Acad Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S37609","article-title":"Alopecia areata: burden of disease, approach to treatment, and current unmet needs","volume":"31","author":"Alhanshali L","year":"2023","unstructured":"Alhanshali L, Buontempo MG, Lo Sicco KI, Shapiro J. Alopecia areata: burden of disease, approach to treatment, and current unmet needs. Clin Cosmet Investig Dermatol. 2023, 31:803-20. 10.2147\/CCID.S37609","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing M","year":"2022","unstructured":"Lensing M, Jabbari A. An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata. Front Immunol. 2022, 13:955035. 10.3389\/fimmu.2022.955035","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5455\/njppp.2023.13.02072202313022023","article-title":"Analyzing the role of tofacitinib in treatment of alopecia areata: a retrospective analysis from a tertiary care center of North India","volume":"4","author":"Singla S","year":"2023","unstructured":"Singla S, Narang R, Shanker V, Gupta S, Saraswat N, Singh R. Analyzing the role of tofacitinib in treatment of alopecia areata: a retrospective analysis from a tertiary care center of North India. Natl J Physiol Pharm Pharmacol. 2023, 4:24-6. 10.5455\/njppp.2023.13.02072202313022023","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon O","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, et al.. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023, 24:443-51. 10.1007\/s40257-023-00764-w","journal-title":"Am J Clin Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/254776-treatment-challenges-in-alopecia-areata-insights-from-a-case-of-baricitinib-therapy-failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:01:20Z","timestamp":1719327680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/254776-treatment-challenges-in-alopecia-areata-insights-from-a-case-of-baricitinib-therapy-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.63120","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}